Corporate News

Biocon Malaysia receives EMA approval for new drug product fill finish line for Semglee' As On :16-Jul-26 09:34

Biocon has received approval from the European Medicines Agency (EMA) for a new drug product fill finish line for Semglee' (insulin glargine) at its insulin manufacturing facility in Malaysia.

Supplies to Europe from this line are expected to begin from Q2FY27.